Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma

• Published in: Cancer science Vol. 111; no. 6; pp. 1899 - 1909
• Main Authors: Deng, Chuangzhong, Xu, Yanyang, Fu, Jianchang, Zhu, Xiaojun, Chen, Hongmin, Xu, Huaiyuan, Wang, Gaoyuan, Song, Yijiang, Song, Guohui, Lu, Jinchang, Liu, Ranyi, Tang, Qinglian, Huang, Wenlin, Wang, Jin
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.06.2020; John Wiley and Sons Inc
• Subjects: Antibodies; Apoptosis; Automation; Biopsy; Bone cancer; Cancer therapies; CD3 antigen; CD8 antigen; Chemotherapy; CIBERSORT; Clinical trials; Gene expression; Histocompatibility antigen HLA; Immune status; Immunohistochemistry; Immunotherapy; Lymphocytes; Lymphocytes T; Macrophages; Medical research; neoadjuvant chemotherapy; Original; Osteosarcoma; Patients; PD-L1 protein; Ribonucleic acid; RNA; Sarcoma; Studies; Tumors; tumor‐infiltrating immune cells; tumor‐infiltrating lymphocytes; tumor-infiltrating immune cells; neoadjuvant chemotherapy; tumor-infiltrating lymphocytes; CIBERSORT; osteosarcoma

Tumor‐infiltrating immune cells play a crucial role in tumor progression and response to treatment. However, the limited studies on infiltrating immune cells have shown inconsistent and even controversial results for osteosarcoma (OS). In addition, the dynamic changes of infiltrating immune cells af...